Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRM-125
- Development stage
- Discontinued
- Lead developer
- Phoenix Rising Management
- Administration
- Oral
01
Overview
PRM-125 is an experimental drug that was developed for the treatment of hypertension. It was initially developed by Phoenix Rising Management and later associated with PRM Pharma. The drug reached Phase 3 clinical trials, where it was evaluated as a once-daily oral therapy to reduce ambulatory blood pressure in adults with primary hypertension. However, development has been discontinued and no further clinical activity is ongoing. The precise mechanism of action for PRM-125 remains unknown, and there are no approved indications or known adverse events reported in public sources[1][2][3].
Beyond the preview
Go deeper on PRM-125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRM-125.